Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rV-NY-ESO-1
- Development stage
- Phase 2
- Lead developer
- Ludwig Cancer Research
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intradermal
01
Overview
rV-NY-ESO-1 is a recombinant vaccinia virus-based cancer vaccine engineered to express the NY-ESO-1 antigen, a highly immunogenic cancer/testis antigen. The vaccine is designed to stimulate both humoral and cellular immune responses against tumors expressing NY-ESO-1 by presenting the antigen in the context of viral infection, thereby enhancing immunogenicity. It has been studied as part of prime/boost regimens (often with fowlpox-based rF-NY-ESO-1) in patients with advanced cancers such as melanoma and epithelial ovarian cancer. Clinical trials have demonstrated that vaccination with rV-NY-ESO-1 can induce robust CD4+ and CD8+ T-cell responses targeting multiple epitopes of NY‑ESO‑1, leading to clinical benefit including disease stabilization and objective tumor responses in some patients[6][8]. The approach leverages the restricted expression pattern of NY‑ESO‑1 (mainly in germ cells and various tumors) to minimize off-target effects while maximizing anti-tumor immunity.
- Other names
- recombinant vaccinia NY-ESO-1 vaccine
02
Targets
NY-ESO-1 TCR (NY-ESO-1-specific T-cell receptor)NY-ESO-1 (New york esophageal squamous cell carcinoma 1)MHC I (MHC class I})
Beyond the preview
Go deeper on rV-NY-ESO-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rV-NY-ESO-1.